Company ProfilePremium

Natural Health Trends Corp.

Company Profile Analysis

Ticker: NHTC

ESOMAR 23 Corporate BadgeISO Certifications Badge
Natural Health Trends Corp. - Company showcase

Year Founded & Workforce

1988

120 Employees

Natural Health Trends Corp. logo

Natural Health Trends Corp. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Natural Health Trends Corp. Overview

Natural Health Trends Corp. is a micro-cap, Delaware-incorporated, Nasdaq-listed direct-selling and e-commerce company that markets wellness supplements, herbal formulations, skincare and lifestyle products under the NHT Global brand. Its economic engine is a single binary-with-unilevel compensation plan operated through an online ordering platform, with roughly 82–83% of revenue booked by its Hong Kong subsidiary and shipped almost entirely to members residing in mainland China through third-party importers of record. The company owns no manufacturing, carries no financial debt, sources finished goods from contract manufacturers, and historically distributed most of its free cash to shareholders. Revenue has contracted from a 2016 peak of USD 287.7 M to USD 39.8 M in FY2025 and an annualised run-rate near USD 30–36 M in 2026, while the active member base has fallen to 26,000. The investment case now rests on liquidation-like balance-sheet value, cost restructuring and the durability of its China-linked member franchise.


Company's own description (paraphrased from FY2025 10-K)

The company describes itself as an international direct-selling and e-commerce business that, through subsidiaries, sells personal care, wellness and "quality of life" products under the NHT Global brand. Its wholly owned subsidiaries have physical presence in the Americas (United States, Canada, Cayman Islands, Mexico, Peru, Colombia), Greater China (Hong Kong, Taiwan, mainland China), Southeast Asia (Malaysia, Singapore), South Korea, Japan, India and Europe, and it serves Russia and Kazakhstan through a local service provider. Management states that most order volume — especially in Hong Kong — is for personal consumption arising from existing members' referrals, and frames its mission as enriching customers' lives while allowing members to earn from product sales.

Business model

Channel: Network marketing (multi-level marketing) executed almost entirely online. Members order through the company's proprietary web platform and personalised replicating websites; substantially all sales occur via the internet, and members pay by card before shipment, so receivables are minimal (FY2025 10-K).

Compensation plan: A "seamless" global binary plan with unilevel features; each product carries bonus-volume points (a percentage of wholesale price); commissions are paid weekly by the enrolling subsidiary on down-line purchases across all markets. Generation bonuses reach up to three generations on purchases and up to seven generations on commissions in some markets. Commission payouts can be capped weekly in dollar terms or as a percentage of sales. No commission is paid for enrolment itself.

China structure: The company holds no China direct-selling licence. Chinese members buy through the Hong Kong e-commerce direct-selling platform (revenue recognised in Hong Kong; goods delivered to third-party importers of record who pay duties) and/or through a separate China e-commerce retail platform that pays no commissions. A preliminary licence application was withdrawn in 2019 on a Chinese authority's recommendation.

Supply: All products are manufactured by a limited number of third-party contract manufacturers located in the United States, South Korea, Hong Kong, Taiwan, Europe and China. Approximately 40% of the product sourcing base was moved from America to East Asia during 2025 to mitigate tariffs (Q4 2025 release).

Cost structure: Commissions consume ~41% of net sales (41.0% FY2025; 40.9% FY2024); gross margin ~74–75%; SG&A ~37% of sales in FY2025.

Revenue model mix (FY2025 10-K)

Revenue component (USD K)FY2024FY2025
Product sales41,72939,017
Administrative fees, freight and other1,5441,080
Less: sales returns-310-321
Total net sales42,96339,776

Product sales therefore represent ~98% of net revenue; there is no subscription, licensing or service revenue of significance. Administrative fees (membership/enrolment-related fees) and freight recovery are the only non-product streams.

Value-chain position, customers and end-markets

NHTC sits at the brand-owner/marketer layer: it designs or co-develops formulations with suppliers, owns private-label trademarks, and controls distribution, compensation and member engagement, while outsourcing manufacturing and much of logistics. Its customers are its "members" — independent contractors who buy for personal consumption, resale, or both — plus "preferred customers" in some markets. No single customer exceeds 10% of sales, but sales concentrate in a few large member networks. End-markets are consumer health supplements (VMS), herbal/TCM-adjacent supplements, skincare and weight-management products, with ≥10% of revenue each from Premium Noni Juice, Triotein™ and the probiotics line (Enhanced Essential Probiotics and Enhanced Biotic Trio).

Independent characterisation

In substance NHTC is a China-consumer health-products marketer operating offshore via Hong Kong, structurally exposed to (i) Chinese regulatory tolerance of cross-border member-driven sales, (ii) Chinese consumer sentiment, and (iii) US–China trade policy (because goods were historically US-made). The model is asset-light and cash-generative only at scale; below ~USD 45 M of revenue the fixed cost base (listing, executive pay, multi-country subsidiaries) has produced operating losses in every year since FY2022. The company has evolved from a growth-oriented MLM into a shrinking, over-capitalised entity whose principal "product" for public shareholders has been capital return — now being curtailed.

Strategy

Stated strategic themes (paraphrased from FY2025 10-K and 2025–2026 earnings calls)

Member success as core objective: The company frames its strategy around helping members achieve health, beauty and financial goals, built on six claimed competencies: culturally aligned field leaders, a disciplined product-launch capability, a comprehensive training ladder, a year-round incentive plan, an easy-entry commission structure, and continuously improving member service.

Cost realignment: "Align costs with global sales performance" to restore profitability (Q3 2025 release).

Supply-chain localisation: Move sourcing closer to Asian demand to reduce tariff exposure and logistics cost.

Digital and AI investment: Refreshed websites, AI-powered member app, AI agents for logistics and service (Q1 2026 call).

Product innovation: New skincare (Soo:vea), weight-management (TwinSlim Coffee/Tomato Soup), digestive (Super Nutri One), anniversary "signature products".

Momentum events: 25th anniversary celebration in Hong Kong (initially targeting ~1,500 attendees per the Feb 2026 release; revised to "more than 1,000" in July 2026) to reconfirm strategy and re-energise members.

Capital return: Commitment to financial discipline, free-cash-flow growth and shareholder returns (Feb 2026 Broady release), operationalised through a reduced dividend and resumed buybacks.

Initiatives in the last 24 months

InitiativeDateTarget / detailStatus
HQ relocation Hong Kong → CaliforniaFeb 2025Reduce Hong Kong political/operational concentrationCompleted
Colombia market entry2,025New in-country ordering and officeLaunched
Supply-chain shift to East Asia2,025~40% of sourcing moved from America to East Asia by Q4 2025Ongoing; gross margin to 75.2% in Q2 2026
Restructuring (workforce optimisation, office downsizing, manufacturing relocation)Announced Nov 2025USD 1.5 M annualised savings; ~USD 250 K one-time charge (actual Q4 2025 charge USD 283 K)Substantially complete; >USD 600 K saved in H1 2026
Dividend reductionEffective Q1 2026Quarterly dividend cut from USD 0.20 to USD 0.10Implemented
Broady block repurchaseFeb 20262,935,227 shares at USD 2.00 (USD 5.9 M); cuts annual dividend outlay by ~USD 1.2 MCompleted
Website/brand refresh; AI member app; AI agents2,026Improve member experience and efficiencyWebsite launched; app/agents in development
Soo:vea skincare launchSep 2025 presaleNew beauty line in Hong KongLaunched
Super Nutri OneQ1 2026Digestion/detox/immunityLaunched
25th anniversary programmeQ3 2026Prizes, incentives, signature productsEvent held/planned in Q3 2026; results not yet reported
Share repurchase resumptionJul 2026USD 15.9 M remaining under programmeAuthorised

Guidance and targets

The company provides no revenue, earnings or medium-term financial targets. The only quantified target is the USD 1.5 M annualised restructuring savings, with most expected in 2026 and the remainder later due to facility timing. No ESG commitments or emissions targets are disclosed.

Products & Services

All products are sold under the NHT Global brand within the Primary Reporting Unit (subsets in China and Russia/Kazakhstan). The company does not publish SKU-level revenue, specifications, or price lists in its filings; pricing is set per market at wholesale/member and retail levels — specific prices not publicly disclosed in filings. Launch years are given only where disclosed.

Wellness (dietary and nutritional supplements — liquids, capsules, tablets, powders)

ProductDescription / function (company category description)Notes
Premium Noni JuiceNoni fruit liquid supplement; antioxidant/general wellness≥10% of revenue; single-source supplier
Triotein™Protein/nutritional supplement≥10% of revenue; single-source supplier
Enhanced Essential ProbioticsDigestive-health probioticPart of probiotics line ≥10% of revenue
Enhanced Biotic TrioPre/pro/postbiotic digestive supplementRenamed from "Biotic Trio" (FY2024 10-K)
Cluster X2™Wellness supplement—
Children's Chewable MultivitaminPaediatric multivitamin—
ReStor Silver™Wellness supplement—
Glucosamine 2200™Joint-health supplement—
FibeRich™Dietary fibre / digestive health—
EnerginEnergy support supplement—
Omega-3 Essential Fatty AcidsHeart health—
StemRenu®Cellular-health supplement—
OcuFocus™Vision health—
CurcuMore™Curcumin-based supplement—
Ultra B ComplexB-vitamin complex—
CalComplexCalcium/mineral supplement—
Collagen SupremeCollagen supplement—
MetaBoostMetabolic support—
RelaxaProRelaxation/sleep support—
Super Nutri OneDigestion, detox and immunity supportLaunched in Q1 2026 (Q1 2026 call)

Herbal (traditional Chinese medicine-inspired)

ProductDescription
LivaPro™Liver-support herbal supplement
Cordyceps Mycelia CS-4™Cordyceps-based herbal supplement
RespFactor™Respiratory-support herbal supplement

Beauty (facial, hand, body and hair care)

ProductNotes
Skindulgence™ Essence GelHydrating gel
Skindulgence® Revitalizing SerumAnti-ageing serum
Skindulgence® Revitalizing Eye CreamEye care
Floraeda Toner and PrimerToner/primer
Botanical Hand Protector™Hand care
Micellion Cleansing WaterCleanser
Root Revive Hair SerumHair/scalp care
Soo:vea Moisturizing CleanserNew skincare line; presale in Hong Kong at end-September 2025
Soo:vea Moisturizing TonerSoo:vea line
Soo:vea Moisturizing BoosterSoo:vea line
Soo:vea Moisturizing CreamSoo:vea line
Beliné Triple Action Day CreamListed first in FY2025 10-K
Discontinued from FY2025 listSkindulgence 30 Minute Firming System, BioCell SC Mask, Airelle® serum/repair complex/eye & lip treatment, Color Awakening Lipstick™, Adamas™ Brightening Night Cream, Skindulgence Probiotic Ampoule, Skindulgence Daily Gentle Facial Cleanser (all in FY2024 list only)

Lifestyle (weight management, vitality)

ProductNotes
Alura Lux™ by NHT GlobalTopical gel for intimate wellness/vitality
Valura Lux™Topical gel (male-oriented counterpart)
LaVie+™Vitality supplement
TwinSlim™ ProbioticsWeight-management probiotic
TwinSlim™ CoffeeWeight-management beverage (new in FY2025 list)
TwinSlim™ Tomato SoupMeal-replacement/weight-management (new in FY2025 list)
NaturalGlo™Beauty-from-within supplement

At-Home Tests

ProductNotes
BioEssence Wellness PanelAt-home kit measuring 17+ biomarkers across cardiovascular, hormonal, inflammatory, metabolic and nutritional health

Discontinued categories (present in FY2024 10-K, absent in FY2025)

CategoryProduct
HomeAquaPur Desktop Water Purifier
DailySmart Sonic Toothbrush

Services and platforms

  • Proprietary web-based ordering and commission engine; personalised replicating member websites (www.nhtglobal.com).

  • Oracle E-Business Suite for finance, inventory, purchasing and costing.

  • Enhanced corporate/member website with refreshed branding launched around Q1 2026; an AI-powered member app and AI agents for logistics and member services were reported as under development (GuruFocus summary of Q1 2026 call).

  • Member training, incentive trips, and events (e.g., Asia Forum in Bangkok, January 2025; incentive trip to Paris, October 2024; Jeju training, June 2024).

Financial Narrative

Sources: FY2024 and FY2025 figures from company filings (10-K and 8-K); FY2021–FY2023 from S&P Global Market Intelligence data (StockAnalysis.com), cross-checked against filed 8-K totals for FY2023 (revenue USD 43,924 K; net income USD 568 K).

Income statement

Revenue CAGR FY2021–FY2025: -9.8% per year (USD 60.01 M → USD 39.78 M). Since the FY2016 peak (USD 287.7 M), revenue has fallen ~86%.

Commentary. Three features dominate. First, gross margin has been remarkably stable at 73.5–75.0%, reflecting premium pricing intrinsic to the MLM channel; the 2026 improvement to ~75% stems from relocating manufacturing to East Asia (Q2 2026 release/Quartr). Second, the business crossed into operating loss in FY2022 and has not recovered: commissions (~41%) and SG&A (~37%) together exceed gross margin at current scale. Reported net income in FY2022–FY2024 was positive only because interest and investment income on a large cash pile (other income USD 1.9 M in FY2024) offset operating losses. As cash was returned to shareholders and the Tax Act liability paid, other income fell to USD 1.24 M in FY2025 and USD 0.49 M in H1 2026, exposing the operating loss. Third, FY2025 included USD 283 K of restructuring charges and an unusual USD 175 K Q4 tax expense despite a pre-tax loss (foreign tax), turning the year to a USD 882 K net loss.

Quarterly trajectory

Q1 2025 and Q3 2025 revenue derived arithmetically from reported half-year and full-year totals. Q2 2026 revenue of USD 7.6 M was the lowest quarterly figure in the dataset, down 23% YoY and 17% QoQ, driven by Chinese consumer caution, regulatory uncertainty that caused some members to pause, and member misconduct in Hong Kong.

H1 2026 vs H1 2025 — Q2 2026 8-K

Restructuring savings were ~USD 300 K per quarter in Q1 and Q2 2026 (>USD 600 K year-to-date); SG&A fell 9% YoY in Q2 2026 but rose as a share of the shrinking revenue base.

Balance sheet

30 June 2026 (Q2 2026 8-K): cash USD 9.50 M; marketable securities USD 9.12 M; total assets USD 29.21 M; current liabilities USD 11.94 M; lease liabilities USD 2.75 M; equity USD 15.20 M; working capital USD 11.77 M; treasury stock USD 30.36 M (up from USD 24.40 M after the Broady repurchase); accumulated deficit USD 38.76 M.

Commentary. The company has never used financial leverage in the period reviewed; "debt" in aggregator data consists solely of operating lease liabilities. Net cash fell from USD 80.7 M (FY2021) to USD 26.9 M (FY2025) and roughly USD 15.9 M (June 2026). The drivers are (i) ~USD 9.2 M per year of dividends, (ii) the 2017 Tax Act transition-tax installments (approx. USD 4.0 M in FY2024 and USD 5.1 M in FY2025, implied by the difference between reported operating cash flow and operating cash flow before installments), (iii) operating losses, and (iv) the USD 5.9 M Broady repurchase in Q1 2026. Deferred revenue (USD 4.2 M at June 2026) and eWallet balances (USD 2.6 M) are member-related liabilities that would need funding in a wind-down scenario.

Cash flow

H1 2026: operating cash flow USD -2.16 M; capex USD -0.44 M (largely leasehold/office related given a USD 1.36 M new right-of-use asset); buybacks USD -5.87 M; dividends USD -1.72 M.

Ratios

ROIC is not meaningful: operating income is negative and invested capital excluding cash is negative (member liabilities exceed operating assets). Net debt/EBITDA and interest coverage are not applicable (no financial debt; no interest expense).

Inflection points. FY2022 marked the shift to operating losses as revenue fell 18%; FY2025 marked the shift to net losses as investment income shrank; Q2 2026 marked a renewed acceleration of decline (-23% YoY) just as restructuring savings began to flow.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (USD Mn)

Segment revenue (USD Mn)FY2021FY2022FY2023FY2024FY2025

Primary Reporting Unit

56.9146.5642.2140.8938.39

China

2.242.021.241.580.95

Russia and Kazakhstan

0.850.560.480.490.44

Total

60.0149.1343.9242.9639.78

Segment Margins & Growth (%) and Revenue by Segment (%)

Segment metric (%)FY2023FY2024FY2025

Primary Reporting Unit YoY growth

-9.3-3.1-6.1

China YoY growth

-38.627.4-39.9

Russia and Kazakhstan YoY growth

-14.32.1-9.4

Primary Reporting Unit share of revenue

96.195.296.5

China share of revenue

2.83.72.4

Russia and Kazakhstan share of revenue

1.11.11.1

Income Statement

Metric (USD Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

60.0149.1343.9242.9639.78

Cost of sales

15.0112.6611.1711.1810.52

Gross profit

45.0036.4732.7531.7929.25

Commissions expense

———17.5716.30

SG&A

———15.5114.76

Operating income

1.57-0.27-1.67-1.30-1.81

Depreciation & amortization

———0.130.11

EBITDA (operating income + D&A)

———-1.17-1.70

Other income, net

———1.921.24

Pre-tax income

1.510.600.750.62-0.57

Income tax provision

———0.050.32

Net income

1.090.310.570.57-0.88

Per-share metric (USD)

Per-share metric (USD)FY2021FY2022FY2023FY2024FY2025

EPS basic

0.090.030.050.05-0.08

EPS diluted

0.090.030.050.05-0.08

Dividends per share

0.800.800.800.800.80

Margin (%)

Margin (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

74.9874.2374.5673.9873.54

Commissions as % of sales

——4240.941.0

Operating margin

2.62-0.55-3.80-3.02-4.54

EBITDA margin

———-2.72-4.27

Pre-tax margin

2.521.231.701.44-1.43

Net margin

1.810.641.291.33-2.22

Revenue growth YoY

-3.33-18.12-10.60-2.19-7.42

Income Statement and Per-Share Data

MetricQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Net sales (USD K)

10,84610,7379,8139,4779,7499,2067,603

Operating income (USD K)

-421-345-333-495-635-474-643

Net income (USD K)

17612215-431-588-154-451

Diluted EPS (USD)

0.020.010.00-0.04-0.05-0.02-0.05

Active members (count)

30,87030,18029,26028,03026,65026,40026,000

Income Statement (Half-Yearly)

Metric (USD K)H1 2025H1 2026

Net sales

20,55016,809

Gross profit

15,16012,624

Commissions expense

8,5006,964

SG&A

7,3386,777

Operating loss

-678-1,117

Other income, net

813485

Net income

137-605

Net cash used in operating activities

-5,151-2,161

Balance Sheet

Metric (USD Mn)FY2021FY2022FY2023FY2024FY2025

Cash & cash equivalents

———13.536.81

Marketable securities

———30.4122.06

Cash + marketable securities

83.8469.6756.1843.9428.87

Inventories

———3.272.05

Total current assets

———50.9834.19

Total assets

———55.3638.43

Total current liabilities

———20.8013.69

Income taxes payable (incl. Tax Act liability)

———4.910.01

Deferred revenue

———6.435.57

Amounts held in eWallets

———3.292.84

Financial debt (short-term)

00000

Financial debt (long-term)

00000

Operating lease liabilities (total)

3.174.123.462.642.00

Net cash (cash + securities − lease liabilities)

80.6865.5452.7141.3026.87

Goodwill & intangibles (separately reported)

———00

Total stockholders' equity

———32.8723.43

Working capital

———30.1820.51

Cash Flow

Metric (USD Mn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

1.02-4.85-4.28-3.37-6.00

Operating cash flow before Tax Act installments

———0.60-0.94

Capital expenditure

-0.23-0.14-0.05-0.06-0.07

Free cash flow

0.79-5.00-4.32-3.42-6.07

Dividends paid

———-9.21-9.21

Share buybacks

———00

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROE (%) — FY2024 on year-end equity; FY2025 on average equity

1.7-3.1

ROA (%) — FY2024 on year-end assets; FY2025 on average assets

1.0-1.9

Current ratio (x)

2.452.50

Lease liabilities / equity (x)

0.080.09

Asset turnover (x) — FY2025 on average assets

0.780.85

Inventory days (FY2025 on average inventory)

—92

Payables days (FY2025 on average payables)

—25

Cash conversion cycle (days, receivables ≈ 0)

—67

Markets

Market (USD K)FY2023FY2024FY2025

Hong Kong (substantially all shipped to members in China)

34,89835,10632,671

Taiwan

2,1811,5911,542

China (e-commerce retail segment)

1,2401,580950

Russia and Kazakhstan

480490444

Europe

733635530

All other markets (Americas, Japan, South Korea, Malaysia/Singapore, India)

4,3923,5613,639

Total

43,92442,96339,776

Region Margins & Growth (%) and Revenue by Region (%)

Market metric (%)FY2024FY2025

Hong Kong YoY growth

0.6-6.9

Taiwan YoY growth

-27.1-3.1

China retail YoY growth

27.4-39.9

Russia and Kazakhstan YoY growth

2.1-9.4

Europe YoY growth

-13.4-16.5

All other markets YoY growth

-18.92.2

Hong Kong share of revenue

81.782.1

Geographic Revenue

Active membersFY2023FY2024FY2025

Hong Kong (incl. China residents)

23,49023,15019,430

Americas

4,0403,3603,460

Taiwan

2,2301,8701,850

Europe

870790640

Russia and Kazakhstan

530600440

Japan

520440340

India

300340210

Malaysia and Singapore

350250220

South Korea

807060

Total

32,41030,87026,650

Share Price & Returns

Reference pointPrice (USD)Source

31 Dec 2025 close

3.09

DEF 14A

~4 Feb 2026

~3.75

Fintool (Q4 2025 coverage)

52-week range (as of ~Aug 2026)

1.50–4.75

StockAnalysis.com

29 Jul 2026 intraday (Q2 print)

~1.58

MarketBeat

24 Sep 2026 close

1.01

StockAnalysis.com

Capital Markets Data (USD)

TSR index (USD 100 at 31 Dec 2022)FY2023FY2024FY2025

Value of USD 100 investment

194.17179.59151.21

Capital Markets

MetricNHTC

Market capitalisation (USD Mn)

8.7

Cash + securities (USD Mn, 30 Jun 2026)

18.6

Enterprise value excl. leases (USD Mn)

-9.9

Enterprise value incl. lease liabilities (USD Mn)

-7.2

EV/EBITDA

not meaningful (negative EV and EBITDA)

EV/Sales (TTM revenue USD 36.0 M)

negative

P/B (book USD 15.2 M; USD 1.77/share)

0.57

Price / net cash per share (~USD 2.17)

0.47

Price/Sales (TTM)

0.24

Dividend per share (USD)

Dividend per share (USD)FY2021FY2022FY2023FY2024FY2025

Regular dividends declared

0.800.800.800.800.80

Analyst Conclusions

Management guidance

No quantitative revenue or earnings guidance. Qualitative outlook (Q2 2026): environment remains challenging in China; additional restructuring savings expected in H2 2026; more aggressive member-support programmes and campaigns; continued investment in products and technology; 25th anniversary to reconfirm strategy.

Consensus

No analyst consensus exists. On simple extrapolation of H1 2026 (USD 16.8 M), FY2026 revenue would land around USD 32–34 M (-15% to -20%), implying a continued operating loss unless H2 savings and anniversary sales outperform — this is an analyst illustration, not a forecast from any source.

Bull case

  1. Deep discount to cash: At ~0.47x net cash per share and 0.57x book, with no debt, even a slow wind-down could return more than the market price, and buybacks at these levels are mechanically accretive.

  2. Cost base resetting: USD 1.5 M annualised savings (~4% of revenue), gross margin at 75%, and the end of Tax Act payments could bring the business close to cash breakeven on an operating basis.

  3. Optionality on China sentiment: A stabilisation in China consumer confidence or US–China trade détente, combined with the anniversary programme, could restore Hong Kong orders, which management described as stable for four quarters before Q2 2026.

Bear case

  1. Accelerating revenue decline: Q2 2026 revenue fell 23% YoY and 17% QoQ; active members down 20% since FY2023 — the shrinking base may outrun cost cuts.

  2. Value leakage: Fixed corporate costs (executive and director pay ~USD 2.2 M), ongoing operating cash burn (USD 2.2 M in H1 2026) and capital returns could erode the cash cushion before any turnaround, while the new 1.1 M-share equity plan introduces dilution.

  3. Binary regulatory/listing risks: Any Chinese enforcement against the cross-border model would impair ~83% of revenue; a sustained sub-USD 1.00 price would trigger Nasdaq deficiency procedures and potential reverse-split or delisting decisions.

Catalysts and monitorables (next 12 months)

  • Q3 2026 results (expected early November 2026): anniversary event impact, Q3 revenue vs Q3 2025 (USD 9.5 M), restructuring savings run-rate.

  • Dividend status: confirmation of any pause/suspension and capital-allocation framework.

  • Pace of open-market buybacks under the USD 15.9 M authorisation.

  • Active member count trajectory (26,000 at June 2026).

  • Any Nasdaq minimum-bid deficiency notice or reverse-split proposal.

  • China regulatory developments and resolution of Hong Kong member misconduct.

  • US–China tariff changes affecting remaining US-sourced products.

  • FY2026 10-K (expected Feb 2027): going-forward risk language on cash flow and dividends.

  • Any strategic-alternatives process or insider buying/selling (executives hold ~10% combined).

Analyst verdict

Natural Health Trends is no longer a growth story or even a stable income story; it is a melting ice cube with a strong balance sheet relative to its equity value. The core facts are stark. Revenue has fallen from USD 60.0 M in FY2021 to a run-rate near USD 32–36 M, the active member base has shrunk 20% since FY2023, and the company has posted operating losses for four consecutive years. Approximately 83% of revenue depends on a cross-border structure into China that operates without a direct-selling licence and that was destabilised again in Q2 2026 by regulatory uncertainty and member misconduct.

Against this, the equity is priced at well under half of net cash. At USD 1.01, the market capitalisation of roughly USD 8.7 M compares with USD 18.6 M of cash and securities and no financial debt at June 2026. That gap reflects rational investor scepticism about whether cash will ever reach shareholders: liabilities to members (deferred revenue, eWallets) must be honoured, operating burn continues, executive compensation is heavy relative to scale, and governance is insular, with long-tenured and consultant-linked directors and no activist or large outside holder after the Broady exit.

The restructuring is real but modest relative to the revenue slide, and the anniversary programme is a one-off stimulus. The decisive variables over the next 12 months are whether management prioritises returning cash — through disciplined buybacks below net cash or a more formal capital-return plan — over funding losses, and whether Hong Kong/China order volumes stabilise after the Q2 shock.

Verdict: Fundamentally negative on the operating business; the shares screen as a deep-value, net-cash special situation whose outcome hinges on capital allocation and governance rather than growth. Absent evidence of stabilising member counts or a clearer capital-return commitment, the risk of value leakage outweighs the apparent discount.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleAgeTenurePrior rolesEducation

Chris T. Sharng

President (principal executive officer); Director

62

President since Feb 2007; director since Mar 2012; joined Aug 2004 as EVP & CFO

CFO, NorthPole Limited (2004); SVP & CFO, Ultrak Inc./American Building Control (2000–2004); Mattel, Inc., latterly VP International Finance (1989–2000)

MBA, Columbia University; bachelor's, National Taiwan University

Timothy S. Davidson (referred to as "Scott Davidson" in earnings releases)

CFO, SVP and Corporate Secretary

55

CFO since Feb 2007; CAO 2004–2007; Secretary since Jan 2014

Corporate Controller, Celion Networks; Manager of Financial Reporting, IP Communications; Audit Manager, Arthur Andersen

Master's in professional accounting, University of Texas at Austin; bachelor's, East Texas A&M University

Directors' Remuneration

Executive / yearSalaryBonusStock awards (phantom shares)All otherTotal

Sharng FY2025

1,000,0000171,60715,7501,187,357

Sharng FY2024

1,000,0000275,76715,5251,291,292

Davidson FY2025

400,000057,44423,030480,474

Davidson FY2024

400,000092,29027,513519,803

Board of Directors

DirectorAgeRoleSinceIndependentBackground

Randall A. Mason

67

Chairman; Audit Committee Chair

Director May 2003; Chair Mar 2006

Yes

Founder/CEO of Marden Rehabilitation Associates (since 1989); BS chemical engineering, University of Pittsburgh

Chris T. Sharng

62

Director; President

Mar 2012

No

See above

Ching C. Wong

67

Director; Nominating & Governance Chair (pre-meeting)

Jun 2020

Yes

Consultant to company 2016–2020; employee 2004–07 and 2009–10; ex-Corporate Controller, North Pole Ltd; PhD Marketing Management (SUFE), law degree (Tsinghua); FCCA

Ellen Sun

57

Director (Audit, Comp, Nominating committees)

May 2026

Yes (board determination)

CFO & CCO, Marquest Asset Management; ex-CPP Investment Board; consultant to NHTC Oct 2018–Mar 2026; former controller of NHTC's Taiwan subsidiary; CPA (US), CPA (Canada)

Major Shareholders

HolderShares%

Renaissance Technologies LLC (13F, Feb 2026)

581,4156.8

Chris T. Sharng

443,3235.2

Timothy S. Davidson

391,1004.6

Randall A. Mason (incl. 23,899 via Marden Rehabilitation)

252,7332.9

Lucy N. Nduati

18,9350.2

All officers, directors & nominees (7 persons)

1,106,09112.9

Competitive Landscape

Key Competitors

CompetitorTypeSegment overlapLatest revenue (verified)Relative positioning

Herbalife Ltd. (HLF)

Global MLM, nutrition

Weight management, supplements, China

FY2025 net sales ~USD 5.0 B (+ ~6% in Q4 2025)

~125x NHTC's revenue; scale leader

Nu Skin Enterprises (NUS)

Global MLM, beauty & wellness

Skincare, supplements, Greater China

FY2025 revenue USD 1.49 B (-14.3%)

Premium beauty/wellness; also shrinking

USANA Health Sciences (USNA)

Global MLM, nutrition

Supplements, Greater China

FY2025 net sales USD 925.3 M (+8%)

Strong China franchise via licensed BabyCare

Amway

Private global MLM

Supplements, beauty; licensed in China

—

Largest licensed China direct seller (industry context)

Infinitus (LKK Health Products)

Private China-licensed direct seller

TCM/herbal health products

—

Direct herbal overlap with LivaPro/Cordyceps

Perfect (China)

Private China-licensed direct seller

Supplements, personal care

—

Mainland incumbent

Tiens Group

Private China-based direct seller

Supplements

—

Mainland incumbent

Jeunesse Global

Private MLM

Anti-ageing skincare, supplements, Asia

—

Asia-heavy peer

Mannatech (MTEX)

Public small-cap MLM

Supplements, Asia exposure

—

Closest US-listed micro-cap analogue

LifeVantage (LFVN)

Public small-cap MLM

Supplements, Japan/Asia

—

Small-cap analogue

Private HK/Taiwan/China small MLMs (unnamed)

Private

Same member pool

—

Company's stated closest competitors

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricNHTCHerbalifeNu SkinUSANA

Revenue (USD Mn)

39.85,0001,490925.3

Revenue growth (%)

-7.4—-14.38.0

Gross margin (%)

73.5———

Operating margin (%)

-4.5———

Recent Developments

No litigation, regulatory enforcement actions, layoffs with headcount figures beyond the restructuring, or guidance revisions were disclosed in this window.

Company Snapshot

$39.8M

Revenue

120

Employees

$8.7M

Market Cap

1988

Founded

California, US

Headquarters

SWOT Analysis

Strengths

  • Debt-free balance sheet with net cash exceeding market cap: USD 18.6 M cash and securities at 30 Jun 2026 vs ~USD 8.7 M market capitalisation (24 Sep 2026).
  • High, stable gross margin: 73.5–75.0% every year FY2021–FY2025; 75.2% in Q2 2026 after supply relocation.
  • Proven China access model: Two decades of cross-border sales to China residents via Hong Kong; ~USD 32.7 M of FY2025 revenue.
  • Restructuring delivering: ~USD 300 K quarterly savings in Q1 and Q2 2026, >USD 600 K year-to-date against a USD 1.5 M annualised target.
  • Tax Act liability retired: Fully paid by end-2025, removing ~USD 4–5 M of annual cash outflow seen in FY2024–FY2025.
  • Core-product loyalty: Reorder share rose and curated bundles grew 10% in FY2025 (Q4 2025 call); three franchises each exceed 10% of revenue.

Weaknesses

  • Extreme concentration: 82.1% of FY2025 revenue (83% in Q2 2026) from Hong Kong, substantially all shipped to China.
  • Persistent operating losses: Operating loss in FY2022–FY2025 and every quarter since at least Q4 2024; FY2025 operating margin -4.5%.
  • Member erosion: Active members down from 32,410 (FY2023) to 26,000 (Jun 2026), -20%; Hong Kong members down 16% in FY2025 alone.
  • Negative cash generation: Operating cash flow negative in each of FY2022–FY2025; FY2025 operating cash outflow USD 0.94 M even before Tax Act payments.
  • Supplier concentration: Noni Juice, Triotein and probiotics each sourced from a single supplier.
  • Fixed-cost burden relative to scale: Executive and director pay of ~USD 2.2 M in FY2025 (~5.5% of revenue); listing and multi-country subsidiary costs on USD 36 M TTM revenue.

Opportunities

  • Accretive buybacks below net cash: USD 15.9 M authorisation remaining while shares trade at ~0.47x net cash per share (~USD 2.17 at June 2026).
  • Further cost savings in H2 2026: Management expects additional restructuring savings beyond the >USD 600 K realised in H1 2026.
  • Anniversary-driven re-engagement: 25th anniversary event and incentive programme in Q3 2026.
  • Americas/LatAm growth: Colombia launch (2025) and Americas member growth (3,360 → 3,460 in FY2025); peers report strong Latin American growth.
  • Digital tools: AI member app and refreshed website could raise productivity per member at low cost.
  • Strategic alternatives: Low valuation and cash-rich balance sheet could attract a take-private or merger with a larger Asian direct seller (speculative; no evidence of process).

Threats

  • China regulatory action: No China licence; history of 2019 campaign; Q2 2026 regulatory uncertainty caused member pauses.
  • US–China trade policy: Tariffs reached 125% in April 2025 and a further 100% threat in October 2025; anti-US-product sentiment.
  • Member misconduct: Q2 2026 Hong Kong policy violations disrupted sales; vicarious liability risk.
  • Nasdaq listing compliance: Share price of USD 1.01 on 24 Sep 2026 is near the USD 1.00 minimum bid requirement.
  • Cash depletion: Cash and securities fell USD 10.3 M in H1 2026 alone (to USD 18.6 M) from buybacks, dividends and operating outflows.
  • Data-privacy law tightening: China Cyber Security Law amendments effective 1 Jan 2026 increase penalties; PIPL cross-border data rules.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2025HQ relocated from Hong Kong to Rolling Hills Estates, CAReduces Hong Kong governance concentration (context, pre-window)
13 Mar 2025Marcum resigns; CBIZ engaged as auditorTechnical change following CBIZ's acquisition of Marcum's attest business; no disagreements
1 Apr 2025Phantom share grants to executives and directorsPerformance-conditioned incentives; all 2025 tranches later forfeited
Apr 2025US tariffs on Chinese goods escalate to 125% before a temporary reductionDirect hit to sentiment toward US-made products in China; catalyst for supply relocation
Late Apr 2025Q1 2025 results: revenue USD 10.7 M, net income USD 122 KLast quarter with operating cash inflow (USD 484 K)
6 May 2025Annual meetingNo director attended in person
Jul 2025Q2 2025 results: revenue USD 9.8 M (-6% YoY), net income USD 15 K; Colombia launchedTariff uncertainty cited; supply chain move to Asia initiated
22 Aug 2025USD 0.20 dividend paidLast full-rate dividend cycle
Late Sep 2025Presale of new Soo:vea skincare line in Hong KongShifted some revenue timing out of Q3
Oct 2025US announces additional 100% tariff on Chinese goods, then a deal reducing general rate to 47%Continued trade volatility (FY2025 10-K)
3 Nov 2025USD 0.20 dividend declared (paid 28 Nov 2025)Final USD 0.20 payment
5 Nov 2025Q3 2025 results: revenue USD 9.5 M (-11% YoY), net loss USD 431 K; restructuring for USD 1.5 M savings; dividend to be cut to USD 0.10Strategic reset
Q4 2025Restructuring charges USD 283 K; ~40% of sourcing moved to East AsiaExecution of cost program
Dec 20252017 Tax Act liability fully paidRemoves ~USD 4–5 M annual cash drain
1 Jan 2026Amendments to China's Cyber Security Law take effectHigher compliance exposure for China data
2 Feb 2026USD 0.10 dividend declared (paid 27 Feb 2026)First reduced dividend
4 Feb 2026Q4/FY2025 results: FY revenue USD 39.8 M (-7%), net loss USD 882 K; active members -14%Return to annual net loss
17 Feb 2026Repurchase of all Broady shares (25.5%) at USD 2.00Stock fell ~11% on the day
20 Feb 2026FY2025 Form 10-K filedShares outstanding 8,577,848
19 Mar 2026Board approves 2026 Equity Incentive Plan (1.1 M shares)Potential dilution ~12.8%
24 Mar 2026Proxy filed; Chan and Nduati not standing; Ellen Sun nominatedBoard refresh, shrink to four
27–29 Apr 2026USD 0.10 dividend declared (paid 22 May); Q1 2026 results: revenue USD 9.2 M (-14%), net loss USD 154 KHK/China orders described as stable for four quarters
Apr 2026Website relaunch; AI member app in development; Super Nutri One launchedDigital/product initiatives
7 May 2026AGM: Mason, Sharng, Sun, Wong elected; 2026 plan approved; CBIZ ratifiedGovernance
29 Jul 2026Q2 2026 results: revenue USD 7.6 M (-23%), net loss USD 451 K; HK member misconduct; buyback resumption (USD 15.9 M capacity)Sharpest decline in dataset; share price fell ~13% intraday to ~USD 1.58
29 Jul 2026Q2 release contains no dividend declaration (prior releases each did)–
Q3 202625th anniversary celebration in Hong KongOutcome to be reported with Q3 results
24 Sep 2026Shares close at USD 1.01Near Nasdaq USD 1.00 minimum bid threshold; market cap ~USD 8.7 M
Early Nov 2026 (expected)Q3 2026 resultsKey test of anniversary impact and cost savings

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue fell from USD 60 Mn in FY2021 to USD 39.8 Mn in FY2025.
Natural Health Trends Corp. — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue6049.143.94339.8
Cost of sales1512.711.211.210.5
Gross profit4536.532.831.829.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.